Arcturus Therapeutics (ARCT) presented its clinical progress at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, emphasizing upcoming data milestones that could drive investor interest. The biotech firm, with a market cap of approximately $401 million, highlighted two key programs—ARCT-810 for ornithine transcarbamylase (OTC) deficiency and ARCT-032 (LunairCF) for cystic fibrosis—each poised for Phase II readouts later this month, alongside regulatory pathway clarity and platform refinements. The company’s self-amplifying mRNA technology, already approved in 32 countries for the KOSTAIVE vaccine, is expected to deliver 30-fold higher protein expression than conventional mRNA, positioning it for oncology and infectious disease partnerships.
ARCT-810, targeting OTC deficiency—a condition affecting about 10,000 patients worldwide—has completed Phase I and Phase II trials in Europe, the U.K., and the U.S. Phase II data, focusing on ammonia and glutamine biomarkers, could provide insights into functional cure potential, as CEO Joseph Payne noted. Meanwhile, ARCT-032’s cystic fibrosis program, which successfully dosed patients at 15 mg daily for 28 consecutive days, continues to refine its biodegradable lipid nanoparticles and nebulizer design, aiming to surpass historical lung-delivery challenges. The program’s endpoints include FEV, LCI, quality-of-life metrics, and high-resolution CT scans, benchmarked against the Cystic Fibrosis Foundation’s REACH normative study.
A critical milestone in Q4 2024 will be the decision to advance ARCT-032 into Phase III, which could unlock up to $40 million in funding from Thermo Fisher, a partner since July 2024. The company’s revenue for the last twelve months stood at $29.4 million, down 76% year-over-year, while its current ratio remains strong at 5.88. Stocks traded between $14.13 and $14.73, with a 52-week high of $24.17 and a year-to-date return of 140%. The beta of 2.47 underscores its volatility, a trait common in biotech stocks. Beyond cystic fibrosis, Arcturus’s platform has attracted attention for its potential in oncology and infectious diseases, with distribution in Japan handled by Meiji.
Payne emphasized the company’s differentiated approach, leveraging next-generation mRNA technology to address unmet needs in rare diseases. For OTC deficiency, the strategy involves replacing deficient enzymes rather than merely scavenging ammonia, a paradigm shift that could redefine treatment paradigms. Meanwhile, cystic fibrosis’s threshold for success is being established through rigorous clinical endpoints, contrasting with the historical challenges of RNA lung delivery. The upcoming data could solidify Arcturus’s position as a catalyst for rare-disease therapies, with regulatory clarity and funding decisions set to shape its growth trajectory in the coming quarters.
